DeCure's autonomous Neuro AI scientist is researching a drug-repurposing hypothesis for photosensitive epilepsy — screening already-approved drugs against its 4-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease modulePhotosensitive epilepsy maps to a 4-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for photosensitive epilepsy is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
sigma non-opioid intracellular receptor 1 (SIGMAR1) — SIGMAR1 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 4-methylphenyldrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5HK1 · 2.5051 Å · ligand 3-(4-methylphenyl)-5-(1-propyl-3,6-dihydro-2H-pyridin-5-yl)-1,2-oxazole (61W). Experimental structure, not a prediction.
What the evidence adds up to
Photosensitivity is a genetically determined trait that usually begins before age 20, peaking around age 12, and may be asymptomatic or trigger epileptic seizures from natural or artificial light. A 2004 follow-up study of 42 patients (age at onset 6 years 9 months, SD 5 years 2 months, range 5 years to 12 years 1 month) with EEG evidence of photosensitive epilepsy found that 36 were treated with valproate monotherapy, four received valproate combined with carbamazepine or lamotrigine, and two received no drugs but only stimulus avoidance. At the end of follow-up, the photoparoxysmal response had disappeared in 25 patients, and 33 patients became seizure-free. The study concluded that seizure control is good and independent of whether photosensitivity itself persists.
A 2025 review describes the photosensitivity model as the only human model allowing proof-of-principle trials of investigational antiseizure medications after a single dose, typically in small groups of patients with epilepsy in single-blinded, placebo-controlled Phase IIa studies. The model uses the photoparoxysmal EEG response as a surrogate for seizures and has been used for 50 years as an unbiased, accurate, inexpensive method to determine potential efficacy before larger add-on trials, irrespective of epilepsy type. Most patients in such trials have generalised epilepsies, but photosensitivity also occurs in focal-onset epilepsies.
The 2012 review notes that management includes non-pharmacological approaches such as avoiding provocative stimuli and wearing tinted glass, alongside pharmacological treatment. It also covers new guidelines for intermittent photic stimulation and addresses epidemiological, genetic, diagnostic, and therapeutic issues. No other drugs beyond valproate, carbamazepine, and lamotrigine are mentioned in the abstracts.
What remains missing is prospective data from larger, randomised, controlled trials that stratify patients by epilepsy type and genetic background, and funding to validate the photosensitivity model against long-term seizure outcomes in diverse populations. The model’s reliance on a surrogate EEG endpoint rather than clinical seizures also requires further confirmation.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Epileptic Disorders · 2012 · 64 citations
Photosensitivity: epidemiology, genetics, clinical manifestations, assessment, and management
AbstractPhotosensitivity is a genetically determined trait that may be asymptomatic throughout life or manifest with epileptic seizures. Photosensitivity usually begins before the age of 20 years with a peak age at onset at around 12. Both natural and artificial light may trigger seizures. Precise investigation must be carried out by intermittent photic stimulation that can elicit a clearly defined EEG response; video-EEG samples are reported to illustrate the various determinants of response and the main factors altering the effectiveness of intermittent photic stimulation. Management of photosensitive epilepsy includes non-pharmacological (e.g. avoidance of the provocative stimuli and wearing appropriate tinted glass) and pharmacological treatment. This review focuses on the emerging aspects of photosensitivity, in particular, the new guidelines for intermittent photic stimulation and briefly addresses epidemiological (in non-epileptic and epileptic subjects), genetic, diagnostic, and therapeutic issues. [Published with video sequences].
Developmental Medicine & Child Neurology · 2004 · 20 citations
Photosensitivity and epilepsy: a follow‐up study
AbstractTo understand the evolution of photosensitivity and to evaluate if its disappearance is related to the response to anticonvulsant therapy, we performed a long‐term study of 42 patients (17 males, 25 females; age at onset 6 years 9 months, SD 5 years 2 months, range 5 years to 12 years 1 month) who had electroencephalography (EEG) evidence of photosensitive epilepsy. Of the patients, 36 were treated with valproate (VPA) monotherapy and four received VPA in combination with other antiepileptic drugs (AEDs), which were carbamazepine and lamotrigine. Two patients were given no drugs, but treated with stimuli avoidance. All patients were investigated with EEG by using intermittent photic stimulation. The photoparoxysmal response indicated the presence of photosensitivity. At the end of follow‐up, the photoparoxysmal response had disappeared in 25 patients. Thirty‐three patients became seizure‐free. Our study confirms that photosensitive epilepsy has a good prognosis for seizure control that is independent of the persistence or disappearance of photosensitivity.
Developmental Medicine & Child Neurology · 2004 · 18 citations
Photosensitivity and epilepsy: a follow-up study
AbstractTo understand the evolution of photosensitivity and to evaluate if its disappearance is related to the response to anticonvulsant therapy, we performed a long-term study of 42 patients (17 males, 25 females; age at onset 6 years 9 months, SD 5 years 2 months, range 5 years to 12 years 1 month) who had electroencephalography (EEG) evidence of photosensitive epilepsy. Of the patients, 36 were treated with valproate (VPA) monotherapy and four received VPA in combination with other antiepileptic drugs (AEDs), which were carbamazepine and lamotrigine. Two patients were given no drugs, but treated with stimuli avoidance. All patients were investigated with EEG by using intermittent photic stimulation. The photoparoxysmal response indicated the presence of photosensitivity. At the end of follow-up, the photoparoxysmal response had disappeared in 25 patients. Thirty-three patients became seizure-free. Our study confirms that photosensitive epilepsy has a good prognosis for seizure control that is independent of the persistence or disappearance of photosensitivity.
Journal of Neuroscience Nursing · 1985 · 10 citations
Photosensitive Epilepsy
AbstractAlthough epilepsy remains an unsolved medical problem, there is a type of epilepsy known as 'photosensitive epilepsy' described in the medical literature that could serve as the window to understanding the pathophysiology of all epilepsies. Photosensitive epilepsy is a seizure phenomenon caused by exposure to bright and/or flickering light. This type of epilepsy has been estimated to occur in one of every 10,000 people. The nurse's role in this pathological state includes meticulous notations of seizure activity, adverse medication reactions, and psychological assessment of the photosensitive epileptic client.
The human photosensitive epilepsy model for clinical proof‐of‐principle trials of novel antiseizure medications. 1. Use of the <scp>EEG</scp> in drug development and characteristics of the model
AbstractClinical development of novel antiseizure medications (ASMs) would benefit from an early proof-of-principle (POP) model. The photosensitivity model, which uses the photoparoxysmal electroencephalography (EEG) response (PPR) as a surrogate for seizures, is currently the only human model that allows POP trials of investigational compounds after a single drug administration. Typically, trials in this model are performed as single-blinded, placebo-controlled Phase IIa POP studies, evaluating a range of doses in small groups of patients with epilepsy. Although most patients in such trials exhibit generalized epilepsies, photosensitivity also occurs in focal-onset epilepsies. In the first part of this review, we describe the use of epileptiform discharges in drug testing, historical development of the photosensitivity model, the genetics and pathophysiology underlying the photosensitive response in patients with epilepsy, clinical characteristics of the patients, and details on drug testing. In the second part of this review, the outcome of numerous drug trials will be described in detail, including a critical discussion of the limitations of the model. In the past 50 years, the original and later standardized photosensitivity model has shown to be an unbiased, accurate, inexpensive method determining the potential efficacy of a novel ASM before entering large add-on trials with chronic drug administration, irrespective of the type of epilepsy.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
